Equisulin R Injection contains human insulin (100 IU/mL) and is indicated for the management of diabetes mellitus requiring insulin therapy. This rapid-acting insulin preparation facilitates the control of blood glucose levels by promoting cellular glucose uptake and inhibiting hepatic glucose production. Equisulin R is administered subcutaneously to improve glycemic control in patients with type 1 and type 2 diabetes when diet, exercise, and oral hypoglycemic agents alone are insufficient. The onset of action typically occurs within 30 minutes, with a peak effect at 2 to 4 hours and a duration of action lasting approximately 6 to 8 hours, making it suitable for preprandial administration. Dosage and timing should be individualized based on patient-specific factors including blood glucose monitoring results, lifestyle, and concomitant medications. Caution is advised to avoid hypoglycemia, the most common adverse effect, which may manifest as sweating, dizziness, or confusion. Proper injection technique and rotation of injection sites are essential to prevent lipodystrophy. Equisulin R should be stored under recommended conditions to maintain potency. It is contraindicated in patients with hypersensitivity to human insulin or any excipients. Close medical supervision is recommended during therapy to optimize glycemic control and minimize adverse effects.